Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Denardo, G. Denardo, A. Natarajan, L. Miers, A. Foreman, C. Gruettner, G. Adamson, R. Ivkov (2007)
Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF--induced thermoablative therapy for human breast cancer in mice.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 48 3
E. Ozkan, Emel Tokmak, N. Kucuk (2011)
Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patientsAnnals of Nuclear Medicine, 25
G. Arora, P. Dubey, J. Shukla, Sourabh Ghosh, G. Bandopadhyaya (2016)
Evaluation of cytotoxic and tumor targeting capability of 177Lu-DOTATATE-nanoparticles: a trailblazing strategy in peptide receptor radionuclide therapyAnnals of Nuclear Medicine, 30
K. Bergstrom (2008)
Editorial [Hot Topic:The Role of Radiopharmaceuticals in Drug Discovery (Guest Editors: Dr. Kalevi Kairemo and Dr. Kim Bergstrom)]Current Radiopharmaceuticals, 1
W. Jong, P. Borm (2008)
Drug delivery and nanoparticles: Applications and hazardsInternational Journal of Nanomedicine, 3
Chandersekhar Bal, S. Gupta, J. Zaknun (2010)
Radiolabeled somatostatin analogs for radionuclide imaging and therapy in patients with gastroenteropancreatic neuroendocrine tumors.Tropical gastroenterology : official journal of the Digestive Diseases Foundation, 31 2
H. Minn, S. Kauhanen, M. Seppänen, P. Nuutila (2009)
18F-FDOPA: A Multiple-Target MoleculeJournal of Nuclear Medicine, 50
(2006)
Somatostatin and the somatostatin receptors: versatile regulators of biological activity
J. Teunissen, D. Kwekkeboom, R. Valkema, E. Krenning (2011)
Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.Endocrine-related cancer, 18 Suppl 1
E. Pauwels, K. Kairemo, P. Erba, Kim Bergstrom (2008)
Nanoparticles in CancerCurrent Radiopharmaceuticals, 1
Q. Tang, Daozhen Chen, W. Xue, J. Xiang, Yong-Chi Gong, Li Zhang, Cai-qin Guo (2011)
Preparation and biodistribution of 188Re-labeled folate conjugated human serum albumin magnetic cisplatin nanoparticles (188Re-folate-CDDP/HSA MNPs) in vivoInternational Journal of Nanomedicine, 6
Sean Wang, A. Bao, Stephanie Herrera, W. Phillips, B. Goins, Cristina Santoyo, F. Miller, R. Otto (2008)
Intraoperative 186Re-Liposome Radionuclide Therapy in a Head and Neck Squamous Cell Carcinoma Xenograft Positive Surgical Margin ModelClinical Cancer Research, 14
Society of nuclear medicine procedure guideline for somatostatin receptor scintigraphy with In - 111 pentetreo - tide ( version 1 . 0 , approved February 21 , 2001 )
R. Riad, M. Kotb, W. Omar, A. Zaher, E. Ebied, A. Pitman, H. Dayem (2011)
I-131 MIBG THERAPY FOR ADVANCED STAGE III & IV NEUROBLASTOMAJournal of Cancer Therapy, 2
G. Gedik, C. Hoefnagel, E. Bais, R. Olmos (2008)
131I-MIBG Therapy in metastatic phaeochromocytoma and paragangliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 35
M. Jong, W. Breeman, R. Valkema, B. Bernard, E. Krenning (2005)
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46 Suppl 1
M. Gabriel, U. Andergassen, D. Putzer, A. Kroiss, D. Waitz, E. Guggenberg, D. Kendler, I. Virgolini (2010)
Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 54 1
P. Surujpaul, C. Gutiérrez-Wing, B. Ocampo-García, F. Ramírez, C. Murphy, M. Pedraza-lópez, M. Camacho-López, G. Ferro-Flores (2008)
Gold nanoparticles conjugated to [Tyr3]octreotide peptide.Biophysical chemistry, 138 3
J. Esser, E. Krenning, J. Teunissen, P. Kooij, A. Gameren, W. Bakker, D. Kwekkeboom (2006)
Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?European Journal of Nuclear Medicine and Molecular Imaging, 33
O. Schillaci (2004)
Functional-anatomical image fusion in neuroendocrine tumors.Cancer biotherapy & radiopharmaceuticals, 19 1
M. McDevitt, D. Chattopadhyay, Barry Kappel, J. Jaggi, Scott Schiffman, C. Antczak, J. Njardarson, R. Brentjens, D. Scheinberg (2007)
Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon NanotubesJournal of Nuclear Medicine, 48
S. Navalkissoor, Dona Alhashimi, A. Quigley, M. Caplin, J. Buscombe (2010)
Efficacy of using a standard activity of 131I-MIBG therapy in patients with disseminated neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 37
K. Xinopoulos, E. Paraskevas (2007)
Somatostatin receptor scintigraphy with In-111 octreotide in the detection of gastroenteropancreatic carcinoids and their metastasesAnnals of Gastroenterology, 16
V. Rufini, M. Calcagni, R. Baum (2006)
Imaging of neuroendocrine tumors.Seminars in nuclear medicine, 36 3
A. Otte, R. Herrmann, A. Heppeler, M. Béhé, E. Jermann, P. Powell, H. Maecke, J. Muller (1999)
Yttrium-90 DOTATOC: first clinical resultsEuropean Journal of Nuclear Medicine, 26
V. Lewington (2003)
Targeted radionuclide therapy for neuroendocrine tumours.Endocrine-related cancer, 10 4
H. Hong, Yin Zhang, Jiangtao Sun, W. Cai (2009)
Molecular imaging and therapy of cancer with radiolabeled nanoparticles.Nano today, 4 5
G. Arora, J. Shukla, Sourabh Ghosh, S. Maulik, A. Malhotra, G. Bandopadhyaya (2012)
PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation DosePLoS ONE, 7
Xu Wang, Lily Yang, Z. Chen, D. Shin (2008)
Application of Nanotechnology in Cancer Therapy and ImagingCA: A Cancer Journal for Clinicians, 58
J. Kunikowska, L. Królicki, A. Hubalewska-Dydejczyk, R. Mikołajczak, A. Sowa-Staszczak, D. Pawlak (2011)
Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?European Journal of Nuclear Medicine and Molecular Imaging, 38
M. Hofmann, H. Maecke, Börner Ar, E. Weckesser, P. Schöffski, M. Oei, J. Schumacher, M. Henze, A. Heppeler, G. Meyer, W. Knapp (2001)
Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary dataEuropean Journal of Nuclear Medicine, 28
BS Zolnik, A Gonzalez-Fernandez, N Sadrieh, MA Dobrovolskaia (2010)
Minireview: nanoparticles and the immune systemEndocrinology, 151
P. Laverman, W. Mcbride, R. Sharkey, A. Eek, Lieke Joosten, W. Oyen, D. Goldenberg, O. Boerman (2010)
A Novel Facile Method of Labeling Octreotide with 18F-FluorineJournal of Nuclear Medicine, 51
D. Kwekkeboom, W. Herder, B. Kam, C. Eijck, M. Essen, P. Kooij (2008)
et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology :, 26
J. Bomanji, W. Wong, M. Gaze, A. Cassoni, W. Waddington, J. Solano, P. Ell (2003)
Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.Clinical oncology (Royal College of Radiologists (Great Britain)), 15 4
B. Zolnik, Á. González-Fernández, N. Sadrieh, M. Dobrovolskaia (2010)
Nanoparticles and the immune system.Endocrinology, 151 2
J. Ardill, T. O'Dorisio (2010)
Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.Endocrinology and metabolism clinics of North America, 39 4
S. Lee, J. Oh, M. Jang, S. Chung (1999)
Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration.Journal of controlled release : official journal of the Controlled Release Society, 59 2
T. Poeppel, I. Binse, S. Petersenn, H. Lahner, M. Schott, G. Antoch, W. Brandau, A. Bockisch, C. Boy (2011)
68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine TumorsThe Journal of Nuclear Medicine, 52
I. Virgolini, P. Patri, C. Novotny, T. Traub, M. Leimer, B. Füger, S. Li, P. Angelberger, M. Raderer, S. Wogritsch, A. Kurtaran, K. Kletter, R. Dudczak (2001)
Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.Annals of oncology : official journal of the European Society for Medical Oncology, 12 Suppl 2
K. Harrington, K. Harrington, C. Lewanski, C. Lewanski, J. Stewart (2000)
Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development.Clinical oncology (Royal College of Radiologists (Great Britain)), 12 1
H. Balon, Stanley Goldsmith, Barry Siegel, Edward Silberstein, E. Krenning, Otto Lang, Kevin Donohoe (2001)
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 42 7
Nazneen Dubey, Raunak Varshney, J. Shukla, A. Ganeshpurkar, P. Hazari, G. Bandopadhaya, A. Mishra, P. Trivedi (2012)
Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analogDrug Delivery, 19
T. Maina, B. Nock, P. Cordopatis, B. Bernard, W. Breeman, A. Gameren, R. Berg, J. Reubi, E. Krenning, M. Jong (2006)
[99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tateEuropean Journal of Nuclear Medicine and Molecular Imaging, 33
M. Brechbiel (2008)
Bifunctional chelates for metal nuclides.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 52 2
M. Jong, R. Valkema, F. Jamar, L. Kvols, D. Kwekkeboom, W. Breeman, W. Bakker, Chuck Smith, S. Pauwels, E. Krenning (2002)
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.Seminars in nuclear medicine, 32 2
E Seregni, M Maccauro, A Coliva, MR Castellani, E Bajetta, G Aliberti (2010)
Treatment with Tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary resultsQ J Nucl Med Mol Imaging, 54
K. Öberg (2011)
Management of neuroendocrine tumors: current and future therapiesExpert Review of Endocrinology & Metabolism, 6
R. Rossin, D. Pan, K. Qi, J. Turner, Xiankai Sun, K. Wooley, M. Welch (2005)
64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 46 7
J. Teunissen, D. Kwekkeboom, E. Krenning (2004)
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 13
Mohanambe Lingappa, Hong-zhao Song, Sarah Thompson, F. Bruchertseifer, A. Morgenstern, G. Sgouros (2010)
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.Cancer research, 70 17
D. Emfietzoglou, Kostas Kostarelos, G. Sgouros (2001)
An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 42 3
L. Bodei, M. Cremonesi, C. Grana, N. Fazio, S. Iodice, S. Baio, M. Bartolomei, D. Lombardo, M. Ferrari, M. Sansovini, M. Chinol, G. Paganelli (2011)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 38
M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, C. Uprimny, P. Kovács, E. Guggenberg, R. Bale, I. Virgolini (2007)
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CTJournal of Nuclear Medicine, 48
E. Vegt, M. Jong, J. Wetzels, R. Masereeuw, M. Melis, W. Oyen, M. Gotthardt, O. Boerman (2010)
Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for PreventionJournal of Nuclear Medicine, 51
Donald Owens, N. Peppas (2006)
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.International journal of pharmaceutics, 307 1
A. Helbok, C. Decristoforo, G. Dobrozemsky, C. Rangger, E. Diederen, Brigitte Stark, R. Prassl, E. Guggenberg (2010)
Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometalsJournal of Liposome Research, 20
P. Laverman, Christopher D'souza, A. Eek, W. Mcbride, R. Sharkey, W. Oyen, D. Goldenberg, O. Boerman (2011)
Optimized labeling of NOTA-conjugated octreotide with F-18Tumour Biology, 33
J. Boudreaux, D. Klimstra, Manal Hassan, E. Woltering, R. Jensen, S. Goldsmith, C. Nutting, D. Bushnell, M. Caplin, James Yao (2010)
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and CecumPancreas, 39
C. Reis, R. Neufeld, A. Ribeiro, F. Veiga (2006)
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.Nanomedicine : nanotechnology, biology, and medicine, 2 1
M. Kopecḱy, F. Trejtnar, M. Lázníček, A. Lázníčková, V. Semecký, T. Maina, B. Nock (2005)
99mTc demotate 1: biodistribution and elimination characteristics in ratsNuclear Medicine Communications, 26
Y. Patel (1999)
Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 20
M. Gotthardt, I. Dijkgraaf, O. Boerman, W. Oyen (2006)
Nuclear medicine imaging and therapy of neuroendocrine tumoursCancer Imaging, 6
R. Fazel-Rezai (2011)
Biomedical Engineering - From Theory to Applications
P. Jager, R. Chirakal, C. Marriott, A. Brouwers, K. Koopmans, K. Gulenchyn (2008)
6-l-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications*Journal of Nuclear Medicine, 49
C. Wehrmann, S. Senftleben, C. Zachert, D. Müller, R. Baum (2007)
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.Cancer biotherapy & radiopharmaceuticals, 22 3
F. Grünwald, S. Ezziddin (2010)
131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.Seminars in nuclear medicine, 40 2
Ronald Weiner, Ronald Weiner, Mathew Thakur, Mathew Thakur (2001)
Radiolabeled peptides in diagnosis and therapy.Seminars in nuclear medicine, 31 4
M. Dobrovolskaia, S. McNeil (2007)
Immunological properties of engineered nanomaterialsNature Nanotechnology, 2
G. Denardo, A. Natarajan, S. Hok, Julie Perkins, M. Cosman, S. Denardo, F. Lightstone, G. Mirick, L. Miers, R. Balhorn (2007)
Pharmacokinetic Characterization in Xenografted Mice of a Series of First-Generation Mimics for HLA-DR Antibody, Lym-1, as Carrier Molecules to Image and Treat LymphomaJournal of Nuclear Medicine, 48
S. Vöö, J. Bucerius, F. Mottaghy (2011)
I-131-MIBG therapies.Methods, 55 3
C. Waldherr, M. Pless, H. Maecke, A. Haldemann, J. Mueller‐Brand (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 12 7
E. Seregni, M. Maccauro, C. Chiesa, L. Mariani, C. Pascali, V. Mazzaferro, F. Braud, R. Buzzoni, M. Milione, A. Lorenzoni, A. Bogni, A. Coliva, S. Vullo, E. Bombardieri (2014)
Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 41
CP Reis, RJ Neufeld, AJ Ribeiro, F Veiga, I Nanoencapsulation (2006)
Methods for preparation of drug-loaded polymeric nanoparticlesNanomedicine, 2
D. Klimstra, I. Modlin, D. Coppola, R. Lloyd, S. Suster (2010)
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging SystemsPancreas, 39
D. Kwekkeboom, B. Kam, M. Essen, J. Teunissen, C. Eijck, R. Valkema, M. Jong, W. Herder, E. Krenning (2010)
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.Endocrine-related cancer, 17 1
A. Al-Nahhas, Z. Win, T. Szyszko, Aviral Singh, C. Nanni, S. Fanti, Domenico Rubello (2007)
Gallium-68 PET: a new frontier in receptor cancer imaging.Anticancer research, 27 6B
K. Harrington, C. Lewanski, J. Stewart (2000)
Liposomes as vehicles for targeted therapy of cancer. Part 1: preclinical development.Clinical oncology (Royal College of Radiologists (Great Britain)), 12 1
K. Harrington, K. Harrington, Sima Mohammadtaghi, P. Uster, D. Glass, A. Peters, R. Vile, J. Stewart (2001)
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 2
Nazneen Dubey, J. Shukla, P. Hazari, Raunak Varshney, A. Ganeshpurkar, A. Mishra, P. Trivedi, G. Bandopadhaya (2012)
Preparation and biological evaluation of paclitaxel loaded biodegradable PCL/PEG nanoparticles for the treatment of human neuroendocrine pancreatic tumor in mice.Hellenic journal of nuclear medicine, 15 1
DJ Kwekkeboom, WW Herder, BL Kam, CH Eijck, M Essen, PP Kooij (2008)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] Octreotate: toxicity, efficacy, and survivalJ Clin Oncol, 26
C. Decristoforo, T. Maina, B. Nock, M. Gabriel, P. Cordopatis, R. Moncayo (2003)
99mTc-Demotate 1: first data in tumour patients—results of a pilot/phase I studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 30
Lingzhou Zhao, Meilin Zhu, Yujie Li, Y. Xing, Jinhua Zhao (2017)
Radiolabeled Dendrimers for Nuclear Medicine ApplicationsMolecules : A Journal of Synthetic Chemistry and Natural Product Chemistry, 22
M. Cremonesi, F. Botta, A. Dia, M. Ferrari, L. Bodei, C. Cicco, A. Rossi, M. Bartolomei, Riccardo Mei, S. Severi, M. Salvatori, G. Pedroli, G. Paganelli (2010)
Dosimetry for treatment with radiolabelled somatostatin analogues. A review.The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 54 1
J. Cwikła, R. Mikołajczak, D. Pawlak, J. Buscombe, A. Nasierowska-Guttmejer, A. Bator, H. Maecke, J. Walecki (2008)
Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETsJournal of Nuclear Medicine, 49
Yuh-Feng Wang, Chao-Ming Fu, Mei-Hua Chuang, T. Cham, M-I Chung (2011)
Magnetically directed targeting aggregation of radiolabelled ferrite nanoparticlesJournal of Nanomaterials, 2011
S. Moghimi, A. Hunter, J. Murray (2001)
Long-circulating and target-specific nanoparticles: theory to practice.Pharmacological reviews, 53 2
D. Kwekkeboom, J. Teunissen, W. Bakker, P. Kooij, W. Herder, R. Feelders, C. Eijck, J. Esser, B. Kam, E. Krenning (2005)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 12
D. Pach, A. Sowa-Staszczak, J. Kunikowska, L. Królicki, M. Trofimiuk, A. Stefańska, M. Tomaszuk, B. Głowa, R. Mikołajczak, D. Pawlak, A. Jabrocka-Hybel, A. Hubalewska-Dydejczyk (2012)
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 102 1
T. Binderup, U. Knigge, A. Loft, J. Mortensen, A. Pfeifer, B. Federspiel, C. Hansen, L. Højgaard, A. Kjaer (2010)
Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PETJournal of Nuclear Medicine, 51
J. Shukla, G. Bandopadhyaya, I. Varma (2005)
188Rhenium(V)-dimercaptosuccinic acid loaded poly(lactic-co-glycolic)acid microspheres for targeted radiotherapy: production and effectivity.Die Pharmazie, 60 8
B. Ocampo-García, F. Ramírez, G. Ferro-Flores, Luis Leon-Rodriguez, C. Santos-Cuevas, E. Morales-Ávila, C. Murphy, M. Pedraza-lópez, L. Medina, M. Camacho-López (2011)
(99m)Tc-labelled gold nanoparticles capped with HYNIC-peptide/mannose for sentinel lymph node detection.Nuclear medicine and biology, 38 1
We present a comprehensive review of Neuroendocrine Tumors (NET) and the current and developing imaging and therapeutic modalities for NET with emphasis on Nuclear Medicine modalities. Subsequently, nanotechnology and its emerging role in cancer management, especially NET, are discussed. The article is both educative and informative. The objective is to provide an insight into the developments made in nuclear medicine and nanotechnology towards management of NET, individually as well as combined together.
Annals of Nuclear Medicine – Springer Journals
Published: Jan 27, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.